| 0 (0%) | 09-28 17:05 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.23 | 1-year : | 27.1 |
| Resists | First : | 21.6 | Second : | 23.2 |
| Pivot price | 0 | |||
| Supports | First : | 19 | Second : | 15.8 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 23.2 | Low : | 19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADRX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Mon, 28 Sep 2026
ADRX (ADRX) Share Price, News, Stock Market Cap NYSE - TechGraph
Mon, 28 Sep 2026
Number of employees of ADARx Pharmaceuticals, Inc. – NASDAQ:ADRX - TradingView
Mon, 28 Sep 2026
HBM Healthcare Investments Increases Its Stake in Portfolio Company ADARx Pharmaceuticals Through IPO - TradingView
Sun, 27 Sep 2026
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention? - Yahoo Finance
Thu, 24 Sep 2026
ADRX IPO News - siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range - renaissancecapital.com
Thu, 24 Sep 2026
Gross margin % of ADARx Pharmaceuticals Inc. – NASDAQ:ADRX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0512e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 6.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 6.13e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|